Lymphoid Neoplasia

Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphoid neoplasia.

U.K. Panel Rejects Venetoclax-Rituximab Combo for CLL

The U.K.’s National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting the combination of venetoclax and rituximab for the treatment...

How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...

Clinical Trials of Leukemia and Lymphoma Drug Placed on Hold

Pharmaceutical manufacturer Affimed has halted two trials of its CD19/CD3-targeting T-cell engager AFM11 following reports of three serious adverse events (AEs), including one patient...

Patient Dies After Developing Resistance to CAR T-Cell Therapy

A young patient with B-cell acute lymphocytic leukemia who received chimeric antigen receptor (CAR) T-cell therapy developed a resistance to his treatment, according to...

FDA Approves Duvelisib for Patients with CLL or SLL

The U.S. Food and Drug Administration has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia...

FDA Approves NGS-Based Test for Patients With ALL or MM

The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal residual disease (MRD) in...

European Commission Expands Blinatumomab’s Approval for ALL

The European Commission (EC) has approved an expanded indication for blinatumomab to include the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-negative) relapsed or...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...
Advertisement

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.